Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital

Fri, 07 Aug 2026 11:45:00 -0400

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio

AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).

A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Tue, 28 Jul 2026 11:45:00 -0400

International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio
AI + Cellvizio increases accuracy in detecting high-risk lesions from 53% to 87%

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
A new international interobserver study — Proven reproducibility across

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Tue, 21 Jul 2026 11:45:00 -0400

H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026

5:50 p.m. (CEST) – French Session: Click here to register

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Tue, 21 Jul 2026 11:45:00 -0400

H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026

5:50 p.m. (CEST) – French Session: Click here to register

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Tue, 21 Jul 2026 11:45:00 -0400

H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026

5:50 p.m. (CEST) – French Session: Click here to register

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Tue, 21 Jul 2026 11:45:00 -0400

H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026

5:50 p.m. (CEST) – French Session: Click here to register

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Thu, 16 Jul 2026 11:56:00 -0400

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.
Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.
Advance registration is required to participate in the event.
Webinar for shareholders and

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Thu, 16 Jul 2026 11:56:00 -0400

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.
Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.
Advance registration is required to participate in the event.
Webinar for shareholders and

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Thu, 16 Jul 2026 11:56:00 -0400

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.
Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.
Advance registration is required to participate in the event.
Webinar for shareholders and

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Thu, 16 Jul 2026 11:56:00 -0400

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.
Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.
Advance registration is required to participate in the event.
Webinar for shareholders and

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Wed, 15 Jul 2026 13:44:00 -0400

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months
Financing with an existing shareholder intended to secure the Company’s path to cash flow break-even
Maximum dilution of approximately 11% in case of repayment in shares

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Wed, 15 Jul 2026 13:44:00 -0400

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months
Financing with an existing shareholder intended to secure the Company’s path to cash flow break-even
Maximum dilution of approximately 11% in case of repayment in shares

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Wed, 15 Jul 2026 13:44:00 -0400

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months
Financing with an existing shareholder intended to secure the Company’s path to cash flow break-even
Maximum dilution of approximately 11% in case of repayment in shares

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Wed, 15 Jul 2026 13:44:00 -0400

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months
Financing with an existing shareholder intended to secure the Company’s path to cash flow break-even
Maximum dilution of approximately 11% in case of repayment in shares

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Mon, 06 Jul 2026 12:00:00 -0400

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation

Total number of voting rights

Gross Total (1)

StreetInsider.com News Articles

Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital